Keywords: sanofi-aventis, insulin, city, solostar, investments, paying, dividends
Sanofi-Aventis' "insulin city" and SoloSTAR investments paying dividends
Article | 25 February 2008
Sanofi-Aventis' decision to invest 150.0 million euros ($220.7 million) in "insulin city," its insulin device R&D and fully-automated manufacturing base in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
